SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: li35111/20/2019 12:05:29 PM
11 Recommendations

Recommended By
corndog
diaperdaddy
drtom1234
idahoranch1
jhcimmu

and 6 more members

  Read Replies (2) of 63326
 
“ Wells Fargo & Co downgraded shares of Immunomedics (NASDAQ:IMMU) from an outperform rating to a market perform rating in a research report released on Friday morning, Marketbeat Ratings reports. Wells Fargo & Co currently has $18.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $44.00.”

The stagecoach is headed in the other direction, but one day it will return.

——————

By the way, a price target of $18 (a 60% cut) is ridiculous. Either you believe that the CRL will be resolved after a short delay, in which case whatever thesis gave $44 should be pretty much unaffected, or you believe that 132 is not going to be approved, in which case $2 would be appropriate. This is basically a FU to management for the substance-free conference call.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News